Clinical Trial of Comparing DA-2902 and DA-2902-R in Healthy Adult Subjects

An Open-Label, Randomized, Single Oral Dose, Two-Sequence, Two-Period, CrossovSer Bioequivalence Study of "DA-2902" and "DA-2902-R" in Healthy Adults Under Fed Conditions

Status

Completed

Phases

Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT07239453

Enrollment

Registered

2025-11-20

Start date

2025-11-07

Completion date

2025-12-06

Last updated

2026-06-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Infective Disorder

Brief summary

This study is to compare pharmacokinetics and safety profiles of DA-2902 and DA-2902-R in healthy adult subjects

Interventions

DRUGDA-2902

single dose administration (DA-2902 one tablet once a day)

DRUGDA-2902-R

single dose administration (DA-2902-R one tablet once a day)

Study design

Allocation

RANDOMIZED

Intervention model

CROSSOVER

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

19 Years to 44 Years

Healthy volunteers

Yes

Inclusion criteria

* Healthy volunteers * BMI between 18 and 30 kg/m2 * Body weight: Male≥50kg, Female≥45kg * Subjects who have signed an informed consent themselves after receiving detailed explanation about clinical study

Exclusion criteria

* Subjects with clinically significant medical history * Subjects with history of drug abuse or addicted * Subjects with allergy or drug hypersensitivity

Design outcomes

Primary

Measure	Time frame
AUCt	pre-dose ~ 72 hr of pose-dose
Cmax	pre-dose ~ 72 hr of post-dose

Countries

South Korea

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jun 3, 2026